Malondialdehid Plasma Levels Among Patients with Acute Coronary Syndrome in Tertiary Hospital: A Cross Sectional Study

[Speaker] Robby Alfadli:1
[Co-author] Gestina Aliska:2, Mefri Yanni:3, Elly Usman:2, Rahmatini:2, Ivan Mahendra Raditya:3
1:Undergraduate Program, Faculty of Medicine, Andalas University, Indonesia, 2:Department of Pharmacology and Therapeutics, Faculty of Medicine, Andalas University, Indonesia, 3:Department of Cardiology and Vascular Medicine, Faculty of Medicine, Andalas University, Indonesia

Introduction: Acute coronary syndrome (ACS) is a condition of acute myocardial ischemia as a result of atherosclerosis. Oxidative stress contributes in atherosclerosis and it will continue to a process called lipid peroxidation that product is malondialdehyde (MDA). All patients with ACS should use statins as initial therapy in prevention of cardiovascular event. Statins have a pleiotropic effect in healing of vascular membranes that are destroyed by atherosclerosis. The purpose of this study was to observe MDA plasma levels in patients with ACS.

Methods: This research was a descriptive observational with cross sectional study to observe MDA plasma levels. Subject were Patients who underwent cardiac catheterization at Department Cardiology of RS. Dr. M. Djamil Padang period July 2017 - November 2017. MDA plasma levels were analyzed with spectrophotometry.

Results: From 60 patients with ACS showed that predominantly male, ages 40-64 years, and the major risk factors that responsibles were smoker and overweight. The main diagnosed was ST elevation myocardial infarction/STEMI. The mean MDA plasma levels in patients with ACS (2.6±0.54 nm/ml). MDA plasma levels were raised in patients with STEMI (2.62±0.59 nm/ml) as compared to non-ST elevation myocardial infarction/NSTEMI and unstable angina pectoris/UAP (2.61±0.4 nm/ml and 2.44±0.53 nm/ml). We also analized MDA plasma levels in patients based on within and without statin therapy before admission. The MDA plasma levels in patients within statin therapy and without (2.41±0.66 nm/ml vs 2.63±0.52 nm/ml). Patients ACS with dyslipidemia have MDA plasma levels higher than not dyslipidemia (2.58±0.5 nm/ml vs 2,38±0,9 nm/ml).

Conclusions: There are higher MDA plasma levels in STEMI and patients dyslipidemia. Statin therapy may reduce MDA plasma levels.
Advanced Search